Skip to content

Study to Assess the Stability, Efficacy and Safety of the Silent™ Hip Prosthesis in Primary Total Hip Replacement

A Non-comparative, Two Centre, EN540, RSA, Pilot Study to Evaluate the Stability, Efficacy and Safety of the Silent Hip Prosthesis in Primary Total Hip Replacement

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00894140
Enrollment
44
Registered
2009-05-06
Start date
2003-01-31
Completion date
2014-05-31
Last updated
2016-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Keywords

Hip, Cementless, Conservative

Brief summary

The purpose of this study is to determine if the Silent™ hip, when used as part of an artificial hip joint, is stable and effective in treatment of patients with joint disease requiring a total hip replacement. Patients who enter the study will be evaluated at regular intervals following hip surgery using patient, clinical, standard and special x-rays (RSA) to allow the position of the Silent Hip within the bone to be accurately monitored.

Detailed description

The Primary Objective of this study was to evaluate the short-term stability of the Silent Hip, implanted using a manual or navigated technique, using radiostereometric analysis (RSA). The study was also intended to provide the clinical data necessary to demonstrate conformance with the essential requirements of the Medical Device Directive. Secondary objectives were to determine the efficacy of the Silent™ Hip femoral prosthesis from a clinical and radiological prospective, to assess the safety of the device and to evaluate the impact of the procedure on the Subjects' Quality of Life.

Interventions

A short cementless, femoral component for use in total hip arthroplasty

Sponsors

Johnson and Johnson Medical
CollaboratorUNKNOWN
DePuy International
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
25 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Male or female subjects, aged between 25 and 65 years inclusive. 2. Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained. 3. Subjects who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups. 4. Subjects with non-inflammatory osteoarthritis of the hip who require a primary total hip replacement.

Exclusion criteria

1. Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study. 2. Women who are pregnant. 3. Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes. 4. Subjects who have participated in a clinical study with an investigational product in the last 6 month(s). 5. Subjects who are currently involved in any injury litigation claims. 6. Subjects who have osteonecrosis of the femoral neck 7. Subjects who have an existing contralateral hip, ankle or knee replacement or an ipsilateral knee or ankle replacement or any metal implant in the lower lumber spine (navigated cases only). 8. Subjects who are greater than 90kg in weight. 9. Subject who have a CCD angle of the anatomical femur less than 125˚ 10. Subjects with significant bone loss or gross deformity in the region of the neck of the femur as identified on the pre-operative radiographs, where in the Investigator's opinion, there could be considerable migration of the prosthesis or a significant chance of fracture of the femoral shaft and/or the lack of adequate bone to support the prosthesis. 11. Subjects with a Charnley C classification. 12. Subjects with an active local or systemic infection. 13. Subjects with loss of musculature, neuromuscular compromise or vascular deficiency in the affected limb rendering the arthroplasty procedure unjustified. 14. Subjects with Paget's disease 15. Subjects who still plan in the future to have children.

Design outcomes

Primary

MeasureTime frame
The translational and rotational movements of the Silent™ hip in the 3 dimensions from the baseline position (determined from the 7 day post-operative RSA x-rays) to the 1 year follow-up visit.1year post-surgery

Secondary

MeasureTime frame
Difference demonstrated between pre-op and 5 year Harris Hip Score5 years post surgery
Difference demonstrated between pre-op and 5 year Oxford Hip Score5years post surgery
Kaplan Meier survivorship of the Silent Hip prosthesis in terms of revision and radiological aseptic loosening1 year
Difference demonstrated between pre-op and 10 year Harris Hip Score10 years post surgery
Difference demonstrated between pre-op and 10 year Oxford Hip Score10 years post surgery
Incidence of radiological signs on the post-operative x-rays3 months post surgery

Countries

Australia, Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026